AI-ACCELERATED DRUG DISCOVERY

Transcription factor ETV6

Explore its Potential with AI-Driven Innovation
Predicted by Alphafold

Transcription factor ETV6 - Focused Library Design

Available from Reaxense

This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Transcription factor ETV6 including:

1. LLM-powered literature research

Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Transcription factor ETV6 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.

 Fig. 1. Preliminary target research workflow

2. AI-Driven Conformational Ensemble Generation

Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Transcription factor ETV6, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.

 Fig. 2. AI-powered molecular dynamics simulations workflow

3. Binding pockets identification and characterization

We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.

 Fig. 3. AI-based binding pocket detection workflow

4. AI-Powered Virtual Screening

Our ecosystem is equipped to perform AI-driven virtual screening on Transcription factor ETV6. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Transcription factor ETV6. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.

 Fig. 4. The screening workflow of Receptor.AI

Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.

The focused library for Transcription factor ETV6 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Transcription factor ETV6

partner:

Reaxense

upacc:

P41212

UPID:

ETV6_HUMAN

Alternative names:

ETS translocation variant 6; ETS-related protein Tel1

Alternative UPACC:

P41212; A3QVP6; A8K076; Q9UMF6; Q9UMF7; Q9UMG0

Background:

Transcription factor ETV6, known as ETS translocation variant 6 or ETS-related protein Tel1, plays a pivotal role in hematopoiesis and has been implicated in malignant transformation. This protein functions as a transcriptional repressor, binding to the DNA sequence 5'-CCGGAAGT-3', and is crucial in the regulation of gene expression involved in cell growth and development.

Therapeutic significance:

ETV6 is directly involved in the pathogenesis of several hematologic disorders, including Myeloproliferative disorder chronic with eosinophilia, characterized by malignant eosinophils proliferation, and Acute myelogenous leukemia, a severe form of leukemia marked by maturational arrest of hematopoietic precursors. Additionally, it plays a role in Thrombocytopenia 5, a disorder leading to decreased platelet counts and increased risk of malignancies. Understanding the role of ETV6 could open doors to potential therapeutic strategies targeting these diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.